melatonin has been researched along with Hypercholesterolemia in 13 studies
Hypercholesterolemia: A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to investigate the effects of melatonin on the serum asymmetric dimethylarginine (ADMA) levels and the expressions of vaspin, visfatin, dimethylarginine dimethylaminohydrolase (DDAH), and signal transducer and activator of transcription-3 (STAT-3) for evaluation of endothelial function and inflammation in the hypercholesterolemic rats." | 8.31 | The effects of melatonin against atherosclerosis-induced endothelial dysfunction and inflammation in hypercholesterolemic rats. ( Aslan, G; İlhan, N; Sahin, K; Sahna, E; Sezgin, D; Tuzcu, M, 2023) |
| "We have reported recently that nocturnal melatonin levels are reduced in a subgroup of patients with multiple sclerosis (MS)." | 7.69 | The relationship between melatonin secretion and serum cholesterol in patients with multiple sclerosis. ( Awerbuch, GI; Sandyk, R, 1994) |
| " Thus, the antihyperlipemic effect of melatonin, which was first discovered in hypercholesterolemia produced by short- or long-term administration of glucocorticoids, has now been proved to be rather universal and not simply anti-glucocorticoidal." | 5.27 | Effects of melatonin on genetic hypercholesterolemia in rats. ( Aoyama, H; Mori, N; Mori, W, 1988) |
| "The aim of this study was to investigate the effects of melatonin on the serum asymmetric dimethylarginine (ADMA) levels and the expressions of vaspin, visfatin, dimethylarginine dimethylaminohydrolase (DDAH), and signal transducer and activator of transcription-3 (STAT-3) for evaluation of endothelial function and inflammation in the hypercholesterolemic rats." | 4.31 | The effects of melatonin against atherosclerosis-induced endothelial dysfunction and inflammation in hypercholesterolemic rats. ( Aslan, G; İlhan, N; Sahin, K; Sahna, E; Sezgin, D; Tuzcu, M, 2023) |
| "The effect of melatonin on cholesterol metabolism in the rat was investigated in the dietary and hypothyroid models of hypercholesterolemia." | 3.69 | Effect of melatonin on the maintenance of cholesterol homeostasis in the rat. ( Chan, TY; Tang, PL, 1995) |
| "We have reported recently that nocturnal melatonin levels are reduced in a subgroup of patients with multiple sclerosis (MS)." | 3.69 | The relationship between melatonin secretion and serum cholesterol in patients with multiple sclerosis. ( Awerbuch, GI; Sandyk, R, 1994) |
| "Melatonin treatment increased the expression of ATP-binding cassette subfamily A member 1 (ABCA1), which reduced cholesterol accumulation and cholesterol-induced apoptosis." | 1.62 | Melatonin activates ABCA1 via the BiP/NRF1 pathway to suppress high-cholesterol-induced apoptosis of mesenchymal stem cells. ( Chae, CW; Choi, GE; Han, HJ; Jung, YH; Kim, JS; Kim, SY; Lee, HJ; Lee, JE; Lim, JR, 2021) |
| " Thus, the antihyperlipemic effect of melatonin, which was first discovered in hypercholesterolemia produced by short- or long-term administration of glucocorticoids, has now been proved to be rather universal and not simply anti-glucocorticoidal." | 1.27 | Effects of melatonin on genetic hypercholesterolemia in rats. ( Aoyama, H; Mori, N; Mori, W, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Sezgin, D | 1 |
| Aslan, G | 1 |
| Sahin, K | 1 |
| Tuzcu, M | 1 |
| İlhan, N | 1 |
| Sahna, E | 1 |
| Kim, JS | 1 |
| Jung, YH | 1 |
| Lee, HJ | 1 |
| Chae, CW | 1 |
| Choi, GE | 1 |
| Lim, JR | 1 |
| Kim, SY | 1 |
| Lee, JE | 1 |
| Han, HJ | 1 |
| Butun, I | 1 |
| Ekmekci, H | 1 |
| Ciftci, O | 1 |
| Sonmez, H | 1 |
| Caner, M | 1 |
| Altug, T | 1 |
| Kokoglu, E | 1 |
| Benova, T | 1 |
| Knezl, V | 1 |
| Viczenczova, C | 1 |
| Bacova, BS | 1 |
| Radosinska, J | 1 |
| Tribulova, N | 1 |
| Nishida, S | 1 |
| Chan, TY | 1 |
| Tang, PL | 1 |
| Sandyk, R | 1 |
| Awerbuch, GI | 1 |
| Pittalis, S | 1 |
| Lissoni, P | 1 |
| Giani, L | 1 |
| Casati, M | 1 |
| Kropacek, N | 1 |
| Orfanò, S | 1 |
| Giavolucci, F | 1 |
| Merlini, D | 1 |
| Hoyos, M | 2 |
| Guerrero, JM | 2 |
| Perez-Cano, R | 1 |
| Olivan, J | 1 |
| Fabiani, F | 1 |
| Garcia-Pergañeda, A | 1 |
| Osuna, C | 2 |
| Pita, ML | 1 |
| Martin-Lacave, I | 1 |
| Fernández-Santos, JM | 1 |
| Mori, N | 2 |
| Aoyama, H | 2 |
| Murase, T | 1 |
| Mori, W | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase IV Study of Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia[NCT00595504] | Phase 4 | 25 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A comparison between the ramelteon group and the placebo group of change in abdominal fat measured by a DEXA scan, assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | g (Mean) |
|---|---|
| Ramelteon | 3934.86 |
| Placebo (Sugar Pill) | 5120.92 |
A comparison between the ramelteon group and the placebo group of change in insulin resistance measured by the homeostatic model assessment of insulin resistance (HOMA-IR), assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Ramelteon | 2.4 |
| Placebo (Sugar Pill) | 2.36 |
A comparison between the ramelteon group and the placebo group in change in waist circumference (measured in cm) measured at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | cm (Mean) |
|---|---|
| Ramelteon | 106.09 |
| Placebo (Sugar Pill) | 108.37 |
1 review available for melatonin and Hypercholesterolemia
| Article | Year |
|---|---|
Metabolic effects of melatonin on oxidative stress and diabetes mellitus.
Topics: Animals; Anticholesteremic Agents; Diabetes Mellitus; Humans; Hypercholesterolemia; Insulin; Melaton | 2005 |
1 trial available for melatonin and Hypercholesterolemia
| Article | Year |
|---|---|
Effect of a chronic therapy with the pineal hormone melatonin on cholesterol levels in idiopathic hypercholesterolemic patients.
Topics: Administration, Oral; Adult; Anticholesteremic Agents; Cholesterol; Female; Humans; Hypercholesterol | 1997 |
11 other studies available for melatonin and Hypercholesterolemia
| Article | Year |
|---|---|
The effects of melatonin against atherosclerosis-induced endothelial dysfunction and inflammation in hypercholesterolemic rats.
Topics: Animals; Atherosclerosis; Atorvastatin; Hypercholesterolemia; Hyperlipidemias; Inflammation; Melaton | 2023 |
Melatonin activates ABCA1 via the BiP/NRF1 pathway to suppress high-cholesterol-induced apoptosis of mesenchymal stem cells.
Topics: Animals; Apoptosis; ATP Binding Cassette Transporter 1; Carrier Proteins; Humans; Hypercholesterolem | 2021 |
The effects of different doses of melatonin on lipid peroxidation in diet-induced hypercholesterolemic rats.
Topics: Animals; Antioxidants; Cholesterol; Cholesterol, LDL; Hypercholesterolemia; Lipid Peroxidation; Lipo | 2013 |
Acute anti-fibrillating and defibrillating potential of atorvastatin, melatonin, eicosapentaenoic acid and docosahexaenoic acid demonstrated in isolated heart model.
Topics: Animals; Anti-Arrhythmia Agents; Atorvastatin; Cardiac Pacing, Artificial; Docosahexaenoic Acids; Ei | 2015 |
Effect of melatonin on the maintenance of cholesterol homeostasis in the rat.
Topics: Animals; Anticholesteremic Agents; Bile Acids and Salts; Cholesterol; Cholesterol, Dietary; Choleste | 1995 |
The relationship between melatonin secretion and serum cholesterol in patients with multiple sclerosis.
Topics: Adult; Age of Onset; Cholesterol; Cohort Studies; Female; Humans; Hypercholesterolemia; Male; Melato | 1994 |
Melatonin.
Topics: Anticholesteremic Agents; Antioxidants; Drugs, Investigational; Humans; Hypercholesterolemia; Melato | 1999 |
Serum cholesterol and lipid peroxidation are decreased by melatonin in diet-induced hypercholesterolemic rats.
Topics: Animals; Brain; Cholesterol; Cholesterol, Dietary; Enzymes; Free Radical Scavengers; Hypercholestero | 2000 |
Long-term melatonin administration increases polyunsaturated fatty acid percentage in plasma lipids of hypercholesterolemic rats.
Topics: Animals; Aorta; Cholesterol, Dietary; Erythrocyte Membrane; Fatty Acids, Unsaturated; Hypercholester | 2002 |
Anti-hypercholesterolemic effect of melatonin in rats.
Topics: Animals; Cholesterol; Cholesterol, Dietary; Chromatography, High Pressure Liquid; Hypercholesterolem | 1989 |
Effects of melatonin on genetic hypercholesterolemia in rats.
Topics: Animals; Cholesterol; Fatty Liver; Hypercholesterolemia; Hypolipidemic Agents; Kidney; Liver; Male; | 1988 |